70

Bioinformatics of the Brain

[112] L. M. Smits, L. Reinhardt, P. Reinhardt, et al., “Modeling parkinson’s

disease in midbrain-like organoids,” npj Parkinson’s Disease, vol. 5, p. 5,

4 2019.

[113] H. Kim, H. J. Park, H. Choi, et al., “Modeling g2019s-lrrk2 spo-

radic parkinson’s disease in 3d midbrain organoids,” Stem Cell Reports,

vol. 12, pp. 518–531, 3 2019.

[114] D. Doi, H. Magotani, T. Kikuchi, et al., “Pre-clinical study of induced

pluripotent stem cell-derived dopaminergic progenitor cells for parkin-

son’s disease,” Nature Communications, vol. 11, p. 3369, 7 2020.

[115] I. Garitaonandia, R. Gonzalez, T. Christiansen-Weber, et al., “Neural

stem cell tumorigenicity and biodistribution assessment for phase i clin-

ical trial in parkinson’s disease,” Scientific Reports, vol. 6, p. 34478, 9

2016.

[116] Y.-K. Wang, W.-W. Zhu, M.-H. Wu, et al., “Human clinical-grade

parthenogenetic esc-derived dopaminergic neurons recover locomotive

defects of nonhuman primate models of parkinson’s disease,” Stem Cell

Reports, vol. 11, pp. 171–182, 7 2018.

[117] Y. Cha, T.-Y. Park, P. Leblanc, et al., “Current status and future per-

spectives on stem cell-based therapies for parkinson’s disease,” Journal

of Movement Disorders, vol. 16, pp. 22–41, 1 2023.

[118] J. A. Smith, A. M. Nicaise, R.-B. Ionescu, et al., “Stem cell therapies

for progressive multiple sclerosis,” Frontiers in Cell and Developmental

Biology, vol. 9, 7 2021.

[119] E. Grajchen, J. J. A. Hendriks, and J. F. J. Bogie, “The physiology of

foamy phagocytes in multiple sclerosis,” Acta Neuropathologica Commu-

nications, vol. 6, p. 124, 12 2018.

[120] J. Martínez-Larrosa, C. Matute-Blanch, X. Montalban, et al., “Mod-

elling multiple sclerosis using induced pluripotent stem cells,” Journal

of Neuroimmunology, vol. 349, p. 577425, 12 2020.

[121] Y. Xin, J. Gao, R. Hu, et al., “Changes of immune parameters of t lym-

phocytes and macrophages in eae mice after bm-mscs transplantation,”

Immunology Letters, vol. 225, pp. 66–73, 9 2020.

[122] G. Constantin, S. Marconi, B. Rossi, et al., “Adipose-derived mes-

enchymal stem cells ameliorate chronic experimental autoimmune en-

cephalomyelitis,” Stem Cells, vol. 27, pp. 2624–2635, 10 2009.

[123] Y. Liu, Y. Ma, B. Du, et al., “Mesenchymal stem cells attenuated blood-

brain barrier disruption via downregulation of aquaporin-4 expression

in eae mice,” Molecular Neurobiology, vol. 57, pp. 3891–3901, 9 2020.